-
Patent layout of the world's first Duchenne muscular dystrophy new drug eteplirsen
Time of Update: 2021-11-05
Figure 2 Eteplirsen branched chain fragment structureIn addition, the patents involved in the nucleic acid modification method phosphorodiamide morpholino oligomer (PMO) are shown in Table 2.
-
Haoyang Biotech and Hunda Biotech reached a strategic cooperation on antibody-conjugated drugs (ADCs)
Time of Update: 2021-11-05
(hereinafter referred to as "Hunda Bio") jointly announced that they will carry out CDMO service strategic cooperation in the professional field of antibody-conjugated drugs (ADCs), and provide new cooperative solutions for domestic innovative antibody-conjugated drug research and development enterprises Scheme .
-
Yatron Pharmaceuticals: Dr. Xinjie Chu served as CSO and Ms. Zhou Xin served as Vice President of Clinical R&D
Time of Update: 2021-11-05
Later, she established the Clinical Research Center of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and served as the executive director of the center .
-
Pfizer announces clinical trial data of mRNA vaccine vaccination in children aged 5-11
Time of Update: 2021-11-05
The data shows that one month after the completion of two doses of vaccination, the SARS-CoV-2 neutralizing antibody geometric mean titer (GMT) induced in children aged 5 to 11 was 1197.
-
Phase 3 clinical success of AstraZeneca/Mersk’s PARP inhibitor Lynparza
Time of Update: 2021-11-05
Lynparza is a PARP inhibitor that was approved by the US FDA in May 2020 for the treatment of mCRPC patients who have undergone a new type of hormone therapy Zytiga or Xtandi (enzalutamide, enzalutamide) and who have a mutation in the HRR gene .
-
Sihuan Pharmaceutical "disrupts" 3.5 billion cardiovascular products, Renfu and Dongyang Pharmaceutical, 5 companies report for production
Time of Update: 2021-11-05
Among them, Metoprolol Succinate Sustained Release Tablets There are 4 manufacturing companies, Hainan Huayitaikang Pharmaceutical, Hefei Heyuan Pharmaceutical, and Foshan Derek Pharmaceuticals, all of which have been approved for imitation of category 4, which are deemed to have been reviewed .
-
Missed the best time to put on the market!
Time of Update: 2021-11-05
However, after analyzing the mid-term data of Phase 1/2 and deciding to accelerate the shift to improved mRNA technology, the company finally abandoned the development of this type of mRNA new crown vaccine .
-
Medical representation continues to decrease
Time of Update: 2021-11-05
. Regarding the impact of centralized procurement on domestic and foreign pharmaceutical companies, an industry authority said to Cyberland today that once related products are included in mass procurement, whether they are selected or unsuccessful, the company’s related products do not require pharmaceutical representatives—— This situation has already been manifested earlier, and both Sanofi, who was selected and the unsuccessful Jialin, made the same move and abolished the sales team .
-
Baili Pharmaceutical's EGFR/HER3 double antibody was approved for two clinical trials
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsThe latest announcement by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China shows that the Class 1 new drug SI-B001 bispecific a
-
Zhengda Tianqing, Osaikang... grab 1.5 billion injections!
Time of Update: 2021-11-05
A few days ago, the official website of the State Food and Drug Administration showed that Liaoning Haisco Pharmaceutical's Palonosetron Hydrochloride Injection was approved as a supplementary application.
According to data from Meinenet, the sales of Palonosetron Hydrochloride Injection in China's public medical institutions in 2020 will exceed 1.
-
1 billion cephalosporin injection Haisco overtakes the first review
Time of Update: 2021-11-05
0 Chinese Drug Evaluation DatabaseAccording to data from Mi Nei. com, as of now, Haisco and its subsidiaries have reviewed/deemedly reviewed 19 products (including the approved products this time), of which 10 are injections .
-
The 8th Merck Keytruda new indication is expected to be approved in China in the near future
Time of Update: 2021-11-05
Transfer from | Pharmaceutical Mission HillsAccording to the announcement of the China National Medical Products Administration (NMPA), the listing application for new indications of Merck’s (MSD) PD-1 inhibitor pembrolizumab injection (Keytruda, pembrolizumab) has been updated to: Under review .
Retrieved June 29, 2020, from https:// first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer[3] China Drug Clinical Trial Registration and Information Disclosure Platform.
-
"730 Heights" of generic drug patents
Time of Update: 2021-11-05
Although China's patent information registration platform cannot register crystal patents, after generic drugs are marketed, the original drugs can still be sued for this patent .
-
AbbVie's IL-23 inhibitor is expected to gain the second indication with EU CHMP support
Time of Update: 2021-11-05
Reference materials:[1] AbbVie Receives CHMP Positive Opinion for Risankizumab (Skyrizi®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU).
com/news/ press-releases/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-treatment-adults-with-active-psoriatic-arthritis-in-european-union-eu.
-
New HER2-positive breast cancer drug!
Time of Update: 2021-11-05
The data showed that: HER2 positive in previous treatments with trastuzumab and taxane In patients with unresectable and/or metastatic breast cancer, Enhertu has a significantly better efficacy than Kadcyla, with high and consistent significant benefits observed in multiple efficacy endpoints and key subgroups .
-
Bayer Supports Health Science Lectures Entering Guangzhou Jishan Community
Time of Update: 2021-11-05
The "Healthy China Action·Health Science Popularization Community Action" public welfare lecture will be held on October 14 Walked into Jishan Community in Tianhe District, Guangzhou City, and brought health knowledge lectures with the theme of "Improving Immunity and Protecting Health" .
-
$2 billion psoriasis oral drug first imitation arrow on the string, monoclonal antibody cuts in price and enters medical insurance to compete for the track
Time of Update: 2021-11-05
Under the general trend of entering the national medical insurance catalogue and actively reducing prices of foreign products to compete for the market, monoclonal antibody drugs for the treatment of psoriasis will further expand in the Chinese market .
-
The current dilemma of new drug research and development-the multi-dimensional use of big data and artificial intelligence
Time of Update: 2021-11-05
Xu mentioned that the "AI+Pharmaceutical" model has become an important breakthrough in shortening the drug development process , The addition of AI intelligence and big data technology may change the new drug research and development model, improve research and development efficiency and reduce research and development costs, open a new situation for new drug research and development, and even usher in the outbreak of the biomedical industry .
-
Novavax will participate in the European World Vaccine Conference
Time of Update: 2021-11-05
date: Wednesday, October 20, 2021 time: 11:30 am – 12:00 pm Central European Time (CET) / 5:30–6:00 pm Eastern Daylight Time (EDT) title: Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update Novavax participants: Vivek Shinde, MD, Vice President of Clinical Development date: Wednesday, October 20, 2021 date:
-
Luye Pharma's goserelin microsphere preparation for the treatment of stage III prostate cancer reaches the preset end point
Time of Update: 2021-11-05
The Phase III clinical trial of LY01005 is a randomized, open, positive drug-controlled clinical study to evaluate the effectiveness and safety of continuous intramuscular injection of LY01005 in the treatment of prostate cancer patients .
